Physician profile
Sheena Ogando
NPI 1649564295
$4,616.72
in general payments reported to CMS, 2019-2025
19 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $168 · 2021: $267 · 2022: $403 · 2023: $809 · 2024: $866 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,383.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,232.24 | 2019-2025 | Tavneos, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $632.72 | 2022-2025 | Saphnelo |
| Abbvie INC. | $559.84 | 2019-2025 | |
| Janssen Biotech, INC. | $378.38 | 2025 | Tremfya |
| Ucb, INC. | $322.08 | 2023-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $274.07 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $223.93 | 2020-2023 | Tremfya |
| Janssen Pharmaceuticals, INC | $210.26 | 2025 | Tremfya |
| Genzyme Corporation | $179.99 | 2024 | |
| Novartis Pharmaceuticals Corporation | $158.45 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $135.79 | 2019-2023 | Sotyktu |
| Pfizer INC. | $84.45 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $70.27 | 2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $32.95 | 2025 | Acthar |
| Fresenius Kabi USA, LLC | $31.43 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $25.77 | 2025 | Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $22.45 | 2019 | |
| Bioventus LLC | $21.65 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Ogando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.